Do cytokeratin-positive-only sentinel lymph nodes warrant complete axillary lymph node dissection in patients with invasive breast cancer?

American Surgeon

Volumn 66, Issue 6, 2000, Pages 574-578

  Teng, Steven ^a   Dupont, Elisabeth ^a   McCann, Christa ^a   Wang, Jessica ^a   Bolano, Monica ^a   Durand, Kara ^a   Peltz, Eric ^a   Bass, Siddharth S ^a   Cantor, Alan ^a   Ku, Ni Ni ^a   Cox, Charles E ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN;

ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; TREATMENT INDICATION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LYMPH NODE EXCISION; LYMPH NODES; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

EID: 18344401893     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Cox CE, Bass SS, Ku NN, Berman C, Shons AR, Yeatman TJ, et al. Sentinel lymphadenectomy: a safe answer to less axillary surgery? Recent Results Cancer Res 1998; 152:170-9.
2. Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer (see comments). JAMA 1996;276: 1818-22.
3. Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer (see comments). Ann Surg 1998;227:645-51.
4. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15: 2345-50.
5. Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997;226:271-6.
6. Pendas S, Dauway E, Cox CE, Giuliano R, Ku NN, Schreiber RH, et al. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients. Am Surg 1999;65: 500-5.
7. McIntosh SA, Going JJ, Soukop M, Purushotham AD, Cooke TG. Therapeutic implications of the sentinel lymph node in breast cancer (Letter). Lancet 1999;354:570.
8. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy (see comments) (Review). Ann Surg 1995;222:394-9.
9. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83.
10. Clare SE, Sener SF, Wilkens W, et al. Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann Surg Oncol 1997;4:447-51.
11. Hainsworth PJ, Tjandra JJ, Stillwell RG, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993;80:459-63.
12. de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: Reevaluation with longer follow-up. Br J Cancer 1992;66:523-7.
13. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group (see comments) (Review). Lancet 1990;335:1565-8.
14. Cox CE, Bass SS, Reintgen DS. Techniques for lymphatic mapping in breast carcinoma (Review). Surg Oncol Clin North Am 1900;8:447-68.
15. Cox CE, Hyacinthe M, Gonzalez RJ, Lyman G, Reintgen D, Ku NN, et al. Cytologic evaluation of lumpectomy margins in patients with ductal carcinoma in situ: Clinical outcome. Ann Surg Oncol 1997;4:644-9.
16. Ahmad N, Ku NN, Nicosia SV, Smith P, Muro-Cacho C, Livingstone S, Reintgen DS, Cox CE. Evaluation of sentinel lymph node imprints in breast cancer: Role of intraoperative cytokeratin immunostain in breast cancer staging. Acta Cytol 1998; 42:1218.
17. Jannink I, Fan M, Nagy S, et al. Serial sectioning of sentinel nodes in patients with breast cancer: a pilot study (see comments). Ann Surg Oncol 1998;5:310-4.
18. Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma: Reviewing the dilemma (Review). Cancer 1997;80:1188-97.
19. Chu KU, Turner RR, Hansen NM, et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229:536-41.
20. Cady B. Is axillary lymph node dissection necessary in routine management of breast cancer? No (Review). Important Adv Oncol 1996;251-65.
21. Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981;152:765-72.
22. Copeland EM. Is axillary dissection necessary for T1 carcinoma of the breast? (Editorial). J Am Coll Surg 1997;184:397-8.
23. Moffat FLJ, Senofsky GM, Davis K, et al. Axillary node dissection for early breast cancer: Some is good, but all is better. J Surg Oncol 1992;51:8-13.